A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1
inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The
Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a
robust anti-tumor immune response.